Cases
27 years of market entry — five documented mandates.
From the Zassi pioneer trial in Göttingen (2002) through the trade sale to Hollister (2008) to the NanoVibronix study mandate (2024) — the range of the MEX model.
★ Zassi Bowel Management Systems
- Challenge
- A US pioneer product with no German market structure, no clinical evidence from a German hospital setting and no sales base in the DACH region.
- Result
- Germany became the top EU market at twenty times the volume of the next-best market — followed by the trade sale to Hollister, Inc. (2008).
Ekos Corporation
- Challenge
- A US innovation without clinical evidence in a German context, unclear regulatory requirements for the German launch, and no access to German cardiologists or university hospitals.
- Result
- A clinical study set up at several German university hospitals, a cardiology KOL network established, and FDA data translated into an EU and German setting.
Rüsch Corporation
- Challenge
- An unclear competitive picture in Germany, no pricing strategy, no market share benchmark and no reimbursement clarity for the product class.
- Result
- A nationwide market analysis across hospital owners and care levels, a complete competitor landscape, reimbursement mapping and a successful product launch in German hospitals.
NanoVibronix (UroShield)
- Challenge
- Clinical evidence needed for the German urology market, five KOL hospitals to involve, digital visibility to build in parallel — without marketing and sales drifting apart.
- Result
- A study set-up at 5 KOL sites running alongside an integrated marketing platform — clinical evidence and digital authority in a single mandate. The reference case for Module 7, Digital Authority.
GMP (confidential)
- Challenge
- A specialist market with limited competitive transparency, regulatory complexity, an uncertain price architecture and no established market share benchmarks.
- Result
- A structured market analysis, competitor mapping, price benchmark, reimbursement pathway assessment and a concrete recommendation on market entry strategy and module selection.
Strategy call
Does one of these trajectories match your plans?
In thirty minutes we discuss whether a comparable market entry is realistic for your product — and which modules would carry it.